ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » RA – Diagnosis, Manifestations, & Outcomes Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM
Abstract Number: 1358
A Step Towards Personalised Medicine – Development and Efficacy of Machine Learning Based Smart-Web Application for Prediction of Steroid Induced Hyperglycemia in Patients with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
10:30AM-12:30PM
Abstract Number: 1348
Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs
10:30AM-12:30PM
Abstract Number: 1334
Assessing the Performance of Validated Frailty Instruments in Veterans with Rheumatoid Arthritis (RA)
10:30AM-12:30PM
Abstract Number: 1353
Association Between Frailty and Incident Cancer in Newly Diagnosed Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1356
Association Between Vascular Inflammation and Kidney Function in Patients with Rheumatoid Arthritis: Secondary Analysis of TARGET Trial
10:30AM-12:30PM
Abstract Number: 1359
Association of Coronary Artery Calcium Score and Growth Differentiation Factor 15 in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1327
Association of Rheumatoid Arthritis and Frailty Status with Mortality in Patients with Renal Cell Carcinoma
10:30AM-12:30PM
Abstract Number: 1328
Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study
10:30AM-12:30PM
Abstract Number: 1340
Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease
10:30AM-12:30PM
Abstract Number: 1365
Clinical Conditions Associated with Genetic Predisposition to Rheumatoid Arthritis in Real-World Settings
10:30AM-12:30PM
Abstract Number: 1362
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
10:30AM-12:30PM
Abstract Number: 1333
Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study
10:30AM-12:30PM
Abstract Number: 1351
Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements
10:30AM-12:30PM
Abstract Number: 1331
Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?
10:30AM-12:30PM
Abstract Number: 1346
Early Diagnosis of Rheumatoid Arthritis: Role of Joint Ultrasound Assessment
10:30AM-12:30PM
Abstract Number: 1341
Evaluation of Width Range Index (WRI) and Neutrophil-to-Lymphocyte Ratio (NLR) in Assessing Disease Activity in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1332
Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1344
Forced Vital Capacity Trajectories and Risk of Lung Transplant and ILD-Related Mortality Among Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 1337
Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
10:30AM-12:30PM
Abstract Number: 1355
Genetically-determined Variation in C-reactive Protein Impacts Disease Activity Assessment in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1338
Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
10:30AM-12:30PM
Abstract Number: 1343
Heightened Gout Risk in Patients with Rheumatoid Arthritis: A National Cohort Study
10:30AM-12:30PM
Abstract Number: 1360
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
10:30AM-12:30PM
Abstract Number: 1330
Increased Levels of F-calprotectin in Patients with Early Rheumatoid Arthritis at Diagnosis
10:30AM-12:30PM
Abstract Number: 1347
Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
10:30AM-12:30PM
Abstract Number: 1329
Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty
10:30AM-12:30PM
Abstract Number: 1357
Kidney Function in Rheumatoid Arthritis: Estimating Glomerular Filtration Rate Using Creatinine versus Cystatin C in a Secondary Analysis of the TARGET Trial
10:30AM-12:30PM
Abstract Number: 1345
Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study
10:30AM-12:30PM
Abstract Number: 1364
Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group
10:30AM-12:30PM
Abstract Number: 1363
Prevalence and Predictors of Orthopaedic Surgery in Rheumatoid Arthritis After 12-Years’ Follow-Up (ESPOIR Cohort)
10:30AM-12:30PM
Abstract Number: 1350
Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1324
Rheumatoid Arthritis Associated Interstitial Lung Disease – Patient Perceptions and Recommendations
10:30AM-12:30PM
Abstract Number: 1336
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
10:30AM-12:30PM
Abstract Number: 1325
The Association Between the Number of Teeth and All-Cause as Well as Cardiovascular Mortality Among Patients with RA: NHANES from 1999 to 2004
10:30AM-12:30PM
Abstract Number: 1354
The Association of Genetic Variation in PTPN22 and Rheumatoid Arthritis Disease Activity
10:30AM-12:30PM
Abstract Number: 1335
The Association of Patient-Reported Non-Articular Pain with Musculoskeletal Pain Diagnoses and RA Disease Activity in a Prospective Real-World Cohort of Patients with Early RA
10:30AM-12:30PM
Abstract Number: 1352
The Associations Between Genetic Factors and Rheumatoid Arthritis Treatment Patterns: Data from Two Large Healthcare Systems
10:30AM-12:30PM
Abstract Number: 1361
The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1349
Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 1342
Utility of Anti-Carbamylated Antibodies in Early Rheumatoid Arthritis in South Asian Population
10:30AM-12:30PM
Abstract Number: 1339
When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment
10:30AM-12:30PM
Abstract Number: 1326
Which Biomarkers Indicate Imminent Progression to Inflammatory Arthritis in High Risk CCP Positive Persons?

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology